Amneal Pharmaceuticals Reaps $2.5M in Kentucky Incentives
05/11/2010
"In addition to compelling economic incentives, we recognized that the superb quality and dedication of Glasgow's work force is a key factor in Amneal's reputation for service excellence, so the decision to stay and expand operations in Kentucky was an easy one," said Jim Luce, Amneal executive vice president of sales and marketing.
The Kentucky Economic Development Finance Authority has pre-approved Amneal for tax incentives up to $2.5 million through the Kentucky Business Investment program.
Amneal plans to use the funds to consolidate distribution logistics and sales in a 115,000-square-foot Glasgow facility. It will combine distribution that currently exists in Long Island, New York and Fountain Run, Kentucky. The company develops, manufactures, and distributes generic pharmaceuticals. It is the tenth largest supplier of generic drugs in the country in terms of prescriptions dispensed.
Project Announcements
AMI Metals Expands Spokane, Washington, Production Operations
06/20/2025
Newly Weds Foods Plans Dyersburg, Tennessee, Production Operations
06/20/2025
Yaskawa American Expands Franklin, Wisconsin, Headquarters Operations
06/19/2025
Cayuga Milk Ingredients Expands Cayuga County, New York, Production Operations
06/19/2025
Gap Upgrades Gallatin, Tennessee, Logistics Operations
06/19/2025
Swiss-Based Galderma Plans Miami, Florida, Headquarters Operations
06/19/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
The New Math Behind Mexico and U.S. Manufacturing Decisions
Q2 2025